Upstream Bio, Inc. $UPB Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. trimmed its holdings in shares of Upstream Bio, Inc. (NASDAQ:UPB) by 2.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 132,173 shares of the company’s stock after selling 3,150 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.25% of Upstream Bio worth $809,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Orbimed Advisors LLC acquired a new stake in Upstream Bio during the 4th quarter valued at approximately $93,603,000. Enavate Sciences GP LLC purchased a new position in shares of Upstream Bio during the 4th quarter valued at approximately $40,438,000. VR Adviser LLC purchased a new position in shares of Upstream Bio during the 4th quarter valued at approximately $37,735,000. Wellington Management Group LLP purchased a new position in shares of Upstream Bio during the 4th quarter valued at approximately $25,632,000. Finally, Deep Track Capital LP purchased a new position in shares of Upstream Bio during the 4th quarter valued at approximately $16,440,000.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Upstream Bio from a “sell” rating to a “hold” rating in a report on Friday, June 6th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Upstream Bio has a consensus rating of “Buy” and a consensus price target of $56.50.

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $20.26 on Wednesday. The firm has a fifty day moving average of $14.27 and a 200 day moving average of $10.65. Upstream Bio, Inc. has a one year low of $5.14 and a one year high of $29.46.

Upstream Bio (NASDAQ:UPB) last released its earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13). Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%.The business had revenue of $0.94 million for the quarter, compared to analysts’ expectations of $0.32 million. As a group, equities research analysts forecast that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.